News
|
June 2025, Boston, MA - Bacchus Therapeutics has been selected as a finalist for the prestigious Start-Up Stadium at BIO 2025, the world’s largest biotechnology partnering event. This program is tailored for early-stage companies with fewer than 20 employees and less than $10 million in total funding since inception, offering them a platform to connect with investors and industry leaders. Following the event, two winners will be announced—one in the Seed Stage category and another in the Emerging Start-Up category.
|
May 2025, Blacksburg, VA - Bacchus Therapeutics received "Rising Star in Biotech" award from the Roanoke Blacksburg Technology Council at the Tech Nite 2025 event, held at the campus of Virginia Tech.
Close to 500 leaders, entrepreneurs, and innovators from across Virginia came together to celebrate the Roanoke-Blacksburg region’s vibrant tech and life sciences ecosystem at the RBTC’s 25th annual TechNite, sponsored by Woods Rogers. The landmark event showcased the region’s expanding innovation economy, drawing both statewide and national recognition for its talent, growth, and influence. The night concluded with an awards ceremony recognizing outstanding accomplishments and leadership over the past year—individuals and organizations that are shaping the community and driving its future forward.
Close to 500 leaders, entrepreneurs, and innovators from across Virginia came together to celebrate the Roanoke-Blacksburg region’s vibrant tech and life sciences ecosystem at the RBTC’s 25th annual TechNite, sponsored by Woods Rogers. The landmark event showcased the region’s expanding innovation economy, drawing both statewide and national recognition for its talent, growth, and influence. The night concluded with an awards ceremony recognizing outstanding accomplishments and leadership over the past year—individuals and organizations that are shaping the community and driving its future forward.
|
March 2025, Raleigh, NC - Bacchus Therapeutics has been selected to present at the 2025 Venture Connect Company Showcase, a premier event highlighting breakthrough innovation across the Southeast encompassing both Virginia and North Carolina.
As part of this Shark Tank-style competition, on a theater stage, Bacchus delivered a dynamic five-minute pitch to a live audience of investors, industry leaders, and fellow entrepreneurs. The showcase is designed to boost visibility and accelerate funding opportunities for high-growth startups. Bacchus is honored to represent cutting-edge biotech innovation and share its mission to revolutionize treatment for MYC-driven cancers. |
|
October 2024, Arlington VA - Bacchus Therapeutics was selected to present at the Accelerator Investor Conference—a venture investor and startup forum, as well as an early-stage business competition, that showcases the region as a hub of innovation and opportunity. This selection underscores Bacchus’s momentum and visibility among leading early-stage companies.
|
|
May 2024, Roanoke, VA - At the RAMP Spring 2024 Demo Day, the spotlight was on four outstanding startups that completed the accelerator’s rigorous program: Allis Innovations, Bacchus Therapeutics, Recens Respiratio, and Scanlily. This culminating event offered each company the opportunity to pitch their business to an engaged audience of investors, mentors, and regional leaders, highlighting the progress they made throughout the program and their vision for the future. This Demo Day presentation reflected both scientific innovation and commercial promise, underscoring Bacchus' growing momentum in Virginia’s biotech ecosystem and beyond. The event also served as a celebration of the hard work, milestones, and collaborative spirit that defined the Spring 2024 Cohort.
|
November 2023, Washington DC - At the "Harnessing the Potential of Antibody Drug Conjugates (ADC) in Oncology" event held at JLABS @ Washington D.C., Johnson & Johnson Innovation—together with Carilion Clinic Innovation, Verge Alliance (with support from the City of Roanoke), and the Virginia Tech Corporate Research Center (VTCRC)—announced that Bacchus Therapeutics has been named a winner of the Advancing Oncology InnoVAtion QuickFire Challenge.
This global challenge called on innovators with a vested interest in Virginia’s innovation landscape to submit breakthrough ideas aimed at improving cancer outcomes for adult patients, with possible extensions to pediatric oncology.
This global challenge called on innovators with a vested interest in Virginia’s innovation landscape to submit breakthrough ideas aimed at improving cancer outcomes for adult patients, with possible extensions to pediatric oncology.
|
May 2023, Washington DC - Bacchus Therapeutics was featured in Scaling Curiosity, a life sciences video essay produced by the Prince William County Department of Economic Development, which has been nominated for an Emmy® Award in the Health/Medical – Long Form category.
The film, part of a series highlighting the growth of the bioscience hub at Innovation Park in Manassas, Virginia, showcases Bacchus alongside other local biotech innovators and explores the unique ecosystem that supports the development and success of life sciences companies in the region. |
Research Articles
- A.M. Gouw, L.Eberlin, K. Margulis, D.Sullivan, G. Toal, L. Tong, R. Zare, D.W. Felsher. Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma. PNAS 2017114 (17):4300-4305.
- Shroff EH, Eberlin LS, Dang VM, Gouw AM, Gabay M, Adam SJ, Bellovin DI, Tran PT, Philbrick WM, Garcia-Ocana A, Casey SC, Li Y, Dang CV, Zare RN, Felsher, D. W. MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. Proc Natl Acad Sci U S A. 2015 May 26;112(21):6539-44. doi: 10.1073/pnas.1507228112. Epub 2015 May 11. PMCID: PMC4450371
- A. Le, A.N. Lane, M. Hamaker, S. Bose, A. Gouw, J. Barbi, T. Tsukamoto, C.J. Rojas, B.S. Slusher, H. Zhang, L.J. Zimmerman, D.C. Liebler, R. J. Slebos, P.K. Lorkiewicz, R. M. Higashi, T.W. Fan, C.V.Dang. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metabolism. 2012 Jan 4;15(1):110-21 PMID 22225880
- A. Le, C.R. Cooper, A.M. Gouw, R. Dinavahi, L.M. Deck, R.E. Royer, D.L.V. Jagt, C.V. Dang. Inhibition of Lactate Dehydrogenase A triggers oxidative stress, cell death and diminishes in vivo tumor xenograft growth. Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2037-42. Epub 2010 Jan 19. PMID 20133848
- Y. Xiang, Z.E. Stine, J. Xia, Y. Lu, B.J. Altman, A.L. Hsieh, A.M. Gouw, A. G. Thomas, P. Gao, L. Sun, L. Song, B. Yan, B.S. Slusher, J. Zhuo, L. L. Ooi, C.G.L. Lee, A. Mancuso, A.S.. McCallion, A. Le, S. Rayport, D.W. Felsher, C.V. Dang. On-target inhibition of glutaminase diminishes cell autonomous tumorigenesis. Journal of Clinical Investigations 2015 125(6):2293-306. PMID 25915584
- A. Le, Z.E. Stine, C. Nguyen, J. Afzal, P. Sun, M. Hamaker, N. Siegel, A.M. Gouw, B. Kang, S, Yu, R. Cochran, K.A. Sailor, H.J. Song, C.V. Dang. HypoxCR: a novel fluorescence protein reporter system to envisage differential responses of cells to hypoxia. PNAS 2014 111(34): 12486-91 PMID 2511422
- B. J. Altman, A. L. Hsieh, A. Venkataraman, A. M. Gouw, Z. E. Stine, B. Li, P. Goraksha-Hicks, S. Diskin, D. Bellovin, M. C. Simon, J. C. Rathmell, M. A. Lazar, J. M. Maris, D. W. Felsher, J.B. Hogenesch, C. V. Dang. MYC disruption of the molecular clock in cancer cells. Cell Metab. 2015 Sep 16. pii: S1550-4131(15)00460-X. doi: 10.1016/j.cmet.2015.09.003 PMID 26387865
- E.H. Shroff, V.M. Dang, L. Eberlin, A.M. Gouw, M. Gabay, S.J. Adam, D.I. Bellovin, P. Tran, S.C. Casey, Y. Li, R.V. Nair, S. Plevritis, R. Zare, C.V. Dang, D.W. Felsher. Myc Initiates and Maintains Glutamine-Addicted Renal Cell Adenocarcinoma. PNAS 2015 112 (21): 6539-44. PMID 25964345
- L. Eberlin, M. Gabay, A. Fan, A.M. Gouw, R. Tibshirani, D.W. Felsher, R. Zare. Alterations of the Lipid Profile in Lymphomas Induced by MYC Overexpression. PNAS 2014 111(29):10450-5. PMID 24994904
- S.C. Casey, L. Tong, Y.Li, R. Do, S. Walz, K. Fitzgerald, A.M. Gouw, V. Baylot, I. Guetgemann, M. Eilers, D. W. Felsher. MYC regulates the Anti-Tumor Immune Response through CD47 and PD-L1. Science 2016 Apr 8;352(6282):227-31.
